Skip to main content

Closed

LPCN: Lipocine Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth-82.3% / yr

Operating margin-605.9%

ROIC-53.1%

Financially safe

Stretched

Debt / equity0.00×

Interest coverage0.0×

Current ratio9.99×

Lipocine Inc.

LPCNNASDAQ Capital Market·USD·Closed

Lipocine Inc.

LPCNNASDAQ·USD·Closed

$2.12

+0.38%

$2.12

+$0.01 (0.38%)

52W Range

3thpctl

Volume

0.37×avg

Mkt Cap

12.30MUSD

P/E

-1.1TTM

Div Yield

–ann

52W Range

3thpctl

Volume

0.37×avg

Market Cap

12.30MUSD

P/E Ratio

-1.1TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings